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Objectives: To evaluate the hemodynamics of bladder tumors, we developed a 
method to calculate change in R1 value (∆R1) from T1-dynamic contrast-enhanced 
fast spin-echo magnetic resonance imaging (T1DCE-FSE-MRI). 
Materials and Methods: On a 1.5-T MR system, T1DCE-FSE-MRI was 
performed. This study was applied to 12 patients with urinary bladder tumor, i.e. 
urothelial carcinoma. We compared R1- and SI-time between a peak in the R1- 
and SI-time curve occurred during the first pass within 60 s. Next, we assessed 
the slope of increase for 180 s after CA injection (Slope0-180). 
Results: The mean slope of the first pass was significantly higher for bladder 
tumors on both the ∆R1- and the ∆SI- time curve compared with normal bladder 
walls. Moreover, a significant difference was apparent between bladder tumors 
and normal bladder walls on the mean Slope0-180 in the ∆R1-time curve. However, 
no significant difference in the mean Slope0-180 was observed on the ∆SI-time 
curve between bladder tumors and normal bladder walls. 
Conclusion: T1DCE-FSE-MRI offers three advantages: quantitative analysis; 





images. Use of ∆R1 analysis with T1DCE-FSE-MRI allows more detailed 
information on the hemodynamics of bladder tumors to be obtained and assists in 
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Cystoscopy has initially been used for the diagnosis of bladder tumors, and biopsy 
has generally been performed for the localized diagnosis and characterization of 
tumors. Treatment and prognosis are primarily determined by the invasion depth 
of tumors and the extent of metastases (i.e., staging) 1. Magnetic resonance 
imaging (MRI) is used for staging of bladder tumors, with invasion depth the key 
characteristic used to define disease stage 2, 3. To assess the staging of bladder 
tumors, T2-weighted imaging 2, diffusion-weighted (DW) imaging 4, and dynamic 
contrast-enhanced MRI (DCE-MRI) have been used 4-8. In particular, DCE-MRI 
enables successful separation of bladder tumors from muscle in the early phase. 
Narumi et al 6 demonstrated that oblique DCE-MRI with the spin-echo (SE) 
method showed high staging accuracy, particularly in differentiating between 
superficial tumors and tumors with superficial muscle invasion. Barentsz et al 7 
also reported that evaluation of chemotherapy in advanced bladder tumors could 
be performed using DCE-MRI, it helped detect 13 of 14 responders and eight of 
eight nonresponders after two chemotherapy cycles.  





widely used, and hemodynamics of the tumor are assessed using the signal 
intensity (SI) or change in SI (SI). However, the relationship between the SI and 
the concentration of contrast agent (CA) is not linear 9. To assess the exact 
hemodynamics of the tumor characterization by means of pharmacokinetics 
analysis, inversed T1 (R1) values that are linearly proportional to the concentration 
of CA must be calculated 10. 
 We therefore developed a method to calculate change in R1 value (∆R1) from the 
dynamic contrast-enhanced fast spin-echo (FSE) sequence, and used this method 
to evaluate the hemodynamics of bladder tumors. We describe the basis of this 
method and its clinical usefulness below. 
 
MATERIALS AND METHODS 
Imaging Procedure and Imaging Analysis 
On a 1.5-T MRI system (Intera Achieva 1.5-T; Philips Medical Systems, Best, 
The Netherlands), patients were placed in a supine position with a 5-element 
phased-array coil (as a receiver) wrapped around the pelvis. To achieve moderate 





 To calculate the T1 value of pre-contrast tissue (T10), FSE with spectral 
presaturation with inversion recovery (SPIR) sequences were performed with two 
repetition times (TR: 2TR1=TR2, i.e., TR1=600 ms and TR2=1200 ms). The other 
imaging parameters were 6 ms echo time, 9 echo train length, 192 x 256 matrix, 
300 mm field of view, 15 slices, 4 mm slice thickness, and 0.4 mm intersection 
gap. In addition, pre-saturation slabs parallel to the slices were applied to suppress 
inflow effects. Data acquisition was combined using a parallel imaging technique 
and a phase oversampling technique to suppress aliasing artifacts. 
 Then, gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA BMA; 
Omniscan, Daiichi-Sankyo, Tokyo, Japan) at a dose of 0.1 mmol/kg of body 
weight was administered intravenously using an MR-compatible power injector 
(Sonic Shot 50, Nemoto, Tokyo, Japan) at a rate of 2.0 mL/s, followed by bolus 
injection of 15 mL saline flash. Concurrently, a series of 150 images at 10 time 
points using FSE with SPIR, that is, identical to the pre-contrast sequence 600 ms 
TR, was acquired with a temporal resolution of 20 s. The other imaging 
parameters were set identically at pre-contrast. 





regions of interest (ROI) on the tumor and normal bladder wall in each patient. 
We then set the ROI size for a minimum of 10 pixels. T10 and post-contrast T1 
(T1post) were calculated using the follow equations 11. 
 T10 = -TR1 / ln{(I2pre – I1pre ) / I1pre }      [1] 
 T1post = -TRpost / ln[(-Ipost / Ipre ) • {1 – exp(-TRpost / T10)}+1]   [2] 
where TRpost is post-contrast TR. Moreover, we calculated R1 using the following 
equation: 
 R1 = 1/T1post – 1/T10        [3] 
Then, we compared R1- and SI-time between a peak in the R1- and SI-time 
curve occurred during the first pass within 60 s. Next, we assessed the slope of 
increase for 180 s after CA injection (Slope0-180). 
Study Subjects 
We examined 12 patients (nine men, three women; mean age  standard deviation, 
74.5 ± 7 years; range, 61-87 years) with bladder tumors. Table 1 shows patient 
characteristics. Pathological diagnosis was urothelial carcinoma (i.e., transitional 
cell carcinoma) in all patients. Histopathological confirmation was obtained in all 





SI were made using the nonparametric Wilcoxon signed rank test. Statistical 
analysis was performed using Prism 5 version 5.0b statistical software (GraphPad 
Software, San Diego, CA). P < 0.05 was considered statistically significant. This 
study was approved by the internal review board of our Hospital. Informed 
consent was obtained from all patients. 
 
RESULTS 
Imaging acquisitions were successfully performed for all patients. Consequently, 
∆R1 were calculated for all case. MR images of two clinical cases are shown in 
Fig. 1 and Fig. 2 
 The mean slope of the first pass was significantly higher for bladder tumors on 
the R1-time curve compared with normal bladder walls (P = 0.0156; bladder 
tumor, 0.090 ± 0.04 s-2; normal bladder wall, 0.015 ± 0.01 s-2) (Fig. 3a). The mean 
slope of the first pass was also significantly higher for bladder tumors on the 
∆SI-time curve than for normal bladder walls (P = 0.0223) (Fig. 3b). 
 Moreover, a significant difference was apparent between bladder tumors and 





bladder tumor, 0.017 ± 0.008 s-2; normal bladder wall, 0.007 ± 0.004 s-2) (Fig. 4a). 
However, no significant difference in the mean Slope0-180 was observed on the 




We developed a method to calculate ∆R1 from the dynamic contrast-enhanced 
FSE sequence, and used this method to evaluate the hemodynamics of bladder 
tumors. Figure 5 shows an overview of findings of this study. Changes in R1- 
and SI-time curve of the bladder tumors demonstrated two patterns: one group (n 
= 7) showed a peak during the first pass, and the other group (n = 5) showed a 
rapid increase for 180 s. The significant difference between bladder tumor and 
normal bladder wall groups when assessing the mean gradient of the R1-time 
curve exceeded that of the SI-time curve assessment, indicating the utility of R1 
analysis. Relationships between R1 and CA concentration are linear, which 






 Some reports have been published showing the high accuracy of staging of 
bladder tumors with DCE-MRI using SE or FSE methods 4-6. Other studies have 
demonstrated the ability to track responses to chemotherapy with DCE-MRI with 
the gradient-echo (GRE) method 7. However, in these techniques, imaging of a 
slice or a few slices was acquired from within the target of bladder tumor; thus, 
these methods did not include the whole bladder. Bladder tumors, in general, have 
a high risk of multiple and/or recurrence 12. We could obtain satisfactory slices, 
that is, all bladder images within a thin slice, by using this optimized technique 
and a temporal resolution of 20 s. Besides, we could obtain high-quality images as 
conventional clinical SE images in using this method. Therefore, this method may 
be more useful for assisting in the diagnosis of bladder tumors and for assessing 
response to therapy, such as chemo-radiotherapy or arterial injection of 
chemotherapy. 
 In general, the pulse sequence for DCE-MRI is performed using a GRE sequence, 
that is, spoiled GRE 13, 14. Moreover, several methods for T1 quantification have 
been described. Particularly, the two-flip-angle spoiled GRE method for the 





volume coverage in a relatively short acquisition time. However, it has been 
reported that various effects may render the method vulnerable to systematic 
errors and instabilities (e.g., radio frequency [RF] spoiling, the spatial variability 
of the FA, and a systematic noise bias in the case of low SNR)15. In the pelvic MR 
imaging, the GRE causes much greater susceptibility artifacts due to the effects of 
inhomogeneity of the magnetic field (e.g., pericystic bowel gas). The FSE 
sequence used in this study, which was refocused with a 180˚ pulse, leads to 
absence of influence of inhomogeneity of the magnetic field and thus greatly 
reduces the susceptibility effect 16, 17. Therefore, the main advantage of this 
method is T1 quantification with stable spin-echo signal data instead of unstable 
free induction decay signal data used in GRE. 
 On the other hand, as a limitation of this method, a high-velocity signal loss 
effect has been seen using the SE method 18. For this effect, blood signals in the 
artery or rapid flow structure might not be fully acquired. Therefore, when the 
artery input function for pharmacokinetic analysis is measured using this method, 
we must select the best slice section or slice orientation without a high-velocity 





 Additionally, we could obtain T10 values with this method. Mean values of T10 of 
the bladder tumors and normal bladder walls were 1.295 ± 0.209 s and 0.923 ± 
0.242 s (P = 0.0049), respectively (Fig. 6). Thus, T10 may provide additional 
information for diagnosis 19. However, T10 values do not provide enough data to 
make a diagnosis, as is seen with ΔR1 analysis with hemodynamic evaluation. 
CONCLUSIONS 
 T1DCE-FSE-MRI offers three advantages: quantitative analysis; high-quality 
(i.e., artifact-free) images; and high temporal resolution even for SE images. Use 
of ∆R1 analysis with T1DCE-FSE-MRI allows more detailed information on the 
hemodynamics of bladder tumors to be obtained and assists in differentiation 
between bladder tumors and the normal bladder wall. 
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Fig. 1.  A 61-year-old male with urothelial carcinoma (Patient No. 3). Transverse 
FSE T2- (a) and T1- (b) weighted images. c, d: Transverse FSE with SPIR images 
were performed with two repetition times (TR: 2TR1=TR2, i.e., TR1=600 ms image 
[c] and TR2=1200 ms image [d]) to calculate the T1 value of pre-contrast tissue. e: 
Transverse dynamic contrast-enhanced FSE with SPIR images of this case. A 
series at 10 time points using FSE, that is, identical to the pre-contrast sequence 
600 ms TR, was acquired with a temporal resolution of 20 s. Images were 
acquired after intravenous bolus Gd-DTPA injection, from left to right and top to 
bottom. f: Time-∆R1 curve of this case in ROI analysis.  
 
Fig. 2.  A 80-year-old male with urothelial carcinoma (Patient No. 11). 
Transverse FSE T2- (a) and T1- (b) weighted images. c, d: Transverse FSE with 
SPIR images were performed with two repetition times (TR: 2TR1=TR2, i.e., 
TR1=600 ms image [c] and TR2=1200 ms image [d]) to calculate the T1 value of 
pre-contrast tissue. e: Transverse dynamic contrast-enhanced FSE with SPIR 
images of this case. A series at 10 time points using FSE, that is, identical to the 





Images were acquired after intravenous bolus Gd-DTPA injection, from left to 
right and top to bottom. f: Time-∆R1 curve of this case in ROI analysis. 
 
Fig. 3.  Boxplots showing relationship between bladder tumors and normal 
bladder wall in the first pass slope. (a) ∆R1 analysis. (b) ∆SI analysis. The 
horizontal line is the median, the ends of the box are the upper and lower quartiles, 
and the vertical lines are the full range of values in the data, respectively.  
 
Fig. 4.  Boxplots showing the relationship between bladder tumors and normal 
bladder wall in the Slope0-180. (a) ∆R1 analysis. (b) ∆SI analysis. The horizontal 
line is the median, the ends of the box are the upper and lower quartiles, and the 
vertical lines are the full range of values in the data, respectively. NS: not 
significant. 
 
Fig. 5.  Overview of this study. 
 





wall in the T10-derived FSE method. The horizontal line is the median, the ends of 
the box are the upper and lower quartiles, and the vertical lines are the full range 










































   Table 1 Characteristics of patients 
 
Patient 
No. Sex Age WHO Grade 
Histopathologic 
Stage 
Means of Histopathologic 
Staging  
1 Male 67 G2 > G1 pT1 TUR-Bt 
2 Female 72 G2 ≧pT2a TUR-Bt 
3 Male 61 G3 pT2b TUR-Bt 
4 Male 70 G2 pT2b TUR-Bt 
5 Male 72 G2 pT1 TUR-Bt 
6 Male 72 G2 pT2b TUR-Bt 
7 Female 75 G3 pT2a TUR-Bt 
8 Male 80 G2 pTis TUR-Bt 
9 Male 85 G2 pT1a TUR-Bt 
10 Female 87 G2 ≧pT2b TUR-Bt 
11 Male 80 G3 pT3 Total Cystectomy 
12 Male 73 G2 > G3 pT1 TUR-Bt 
 
WHO, World Health Organization; TUR-Bt, transurethral resection of the bladder tumor 
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